


Chemical Science

Volume 14
Number 19
21 May 2023
Pages 4947–5228

rsc.li/chemical-science



ISSN 2041-6539

Cite this: *Chem. Sci.*, 2023, 14, 4986

All publication charges for this article have been paid for by the Royal Society of Chemistry

Cascade autohydrolysis of Alzheimer's A β peptides†

Martin Wolfram,^{ID}*^a Manish K. Tiwari,[‡]^a Tue Hassenkam,^b Ming Li,^c Morten J. Bjerrum^{ID}^a and Morten Meldal^{*a}

Protein/peptide self-assembly into amyloid structures associates with major neurodegenerative disorders such as Alzheimer's disease (AD). Soluble assemblies (oligomers) of the A β peptide and their aggregates are perceived as neurotoxic species in AD. While screening for synthetic cleavage agents that could break down such aberrant assemblies through hydrolysis, we observed that the assemblies of A β oligopeptides, containing the nucleation sequence A β _{14–24} (H₁₄QKLVFFAEDV₂₄), could act as cleavage agents by themselves. Autohydrolysis showed a common fragment fingerprint among various mutated A β _{14–24} oligopeptides, A β _{12–25}-Gly and A β _{1–28}, and full-length A β _{1–40/42}, under physiologically relevant conditions. Primary endoproteolytic autocleavage at the Gln₁₅-Lys₁₆, Lys₁₆-Leu₁₇ and Phe₁₉-Phe₂₀ positions was followed by subsequent exopeptidase self-processing of the fragments. Control experiments with homologous D-amino acid enantiomers A β _{12–25}-Gly and A β _{16–25}-Gly showed the same autocleavage pattern under similar reaction conditions. The autohydrolytic cascade reaction (ACR) was resilient to a broad range of conditions (20–37 °C, 10–150 μ M peptide concentration at pH 7.0–7.8). Evidently, assemblies of the primary autocleavage fragments acted as structural/compositional templates (autocatalysts) for self-propagating autohydrolytic processing at the A β _{16–21} nucleation site, showing the potential for cross-catalytic seeding of the ACR in larger A β isoforms (A β _{1–28} and A β _{1–40/42}). This result may shed new light on A β behaviour in solution and might be useful in the development of intervention strategies to decompose or inhibit neurotoxic A β assemblies in AD.

Received 8th December 2022
Accepted 3rd April 2023

DOI: 10.1039/d2sc06668h

rsc.li/chemical-science

Introduction

Proteolytic enzymes have evolved to cleave small peptides and proteins with high precision and efficacy.¹ The complex interplay of multiple proteolytic enzymes is vital to the regulation of physiological function by controlling protein maturation, folding, assembly and degradation. During aging the proteostatic network can become defective and collapse.² Proteostatic collapse is characterized by dysregulation of *e. g.* intrinsically disordered proteins (IDPs). Such dysregulation may lead to protein misfolding, polymorphous aggregation and self-propagating amyloid

formation.^{3–6} Accumulating evidence suggests that the soluble oligomeric assemblies of the A β peptide are the neurotoxic species in AD.^{7–13} In solution, A β forms dynamic oligomers which in turn self-assemble into globular oligomers (spherical aggregates) and extended β -sheet structures in distinct folding pathways.^{10,14–18} Unsuccessful attempts of clinical intervention effecting A β clearance involved the design of antibodies that should promote A β uptake into cells with subsequent digestion through proteolytic enzymes.¹⁹ As an alternative, metal-based cleavage agents with the ability for specific molecular recognition and hydrolytic activity towards dysfunctional proteins have been proposed as potential drug candidates for disease intervention.^{20–22} Cobalt(III) complexes of macrocyclic polyamines, in particular, have been found to mediate direct specific cleavage of A β assemblies and thereby disrupt their aggregates.^{23,24} Initially, palladium peptide catalysts were investigated for the cleavage of A β _{14–24}(HQKLVFFAEDV) peptides (ESI Fig. S2C†). During this process, we observed hydrolysis even in the absence of a palladium catalyst and decided to investigate this peculiar metal-independent behaviour of A β peptides in more detail.

While autoproteolytic processing by proteins is considered an evolutionarily conserved mechanism in protein regulation and activation,^{25–29} autoprocessing in the self-assembly of small peptides is a rare phenomenon, not well characterized. One example is the spontaneous hydrolysis of the vasoactive intestinal

^aDepartment of Chemistry, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark. E-mail: martin.wolfram@nano.ku.dk; meldal@chem.ku.dk; Tel: +45 27202355; +45 21308299

^bGlobe Institute, Section for Geobiology, Copenhagen University, Øster Voldgade 5-7, 1350 Copenhagen K, Denmark

^cTechnical University of Denmark, The Danish Hydrocarbon Research and Technology Centre, Elektrovej, 2800 Kongens Lyngby, Denmark

† Electronic supplementary information (ESI) available: The experimental procedures, solid-phase peptide synthesis and analytical methods. Mass spectra, chromatographic data, MS/MS fragment sequencing, results from A β -peptide aggregation assays, CD time laps analysis, AFM images, analysis of hydrolysis screenings and tables describing conditions for repeat experiments. See DOI: <https://doi.org/10.1039/d2sc06668h>

‡ Present address: Novozymes Innovation Campus, Novozymes A/S, Biologiens Vej 2, 2800 Kongens Lyngby.



peptide (VIP).³⁰ The VIP is a neuropeptide,³¹ presenting substantial neuroprotective activities against A β _{25–35} neurotoxicity in relation to AD.³² Intriguingly, recent reports showed that A β oligomers possess intrinsic autoproteolytic properties with autohydrolysis occurring within hours to days.^{33,34} In contrast, non-catalyzed peptide bond hydrolysis in neutral water at 25 °C shows half-times of 300–500 years,³⁵ with the exception of specific acceleration with *e. g.* F–G and D–G containing sequences.³⁶ In their recent report, Mondal and Mandal³⁷ presented a construct with the A β nucleation site LVFFA A β _{17–21} fused to a peptide mimicking serine protease triad that induced hydrolysis of A β _{1–40} along its nucleation site. Furthermore, the peptide YKGSGRMI can promote hydrolysis in A β self-assemblies.³⁸ However, the mechanism of autocatalytic A β self-degradation and thereby, the critical role of fragments containing the A β nucleation site for the mechanism have not been examined, yet probably relevant to Alzheimer's disease.

Here we show evidence for autohydrolysis occurring intrinsically with a characteristic fragment fingerprint to a variety of A β peptides, under physiologically relevant conditions and at room temperature (20 °C). Given the complex dynamic behaviour of amyloidogenic peptides in solution, in a manner that reflects their aggregation potential, we decided to follow an exploratory approach for finding the conditions that drive A β _{14–24} congener autohydrolysis. From a large number of independent experiments, we identified general sequence selective patterns in A β autohydrolysis. We also observed recurring aggregation pathways that lead to these self-assemblies, active in the autohydrolytic cascade reaction (ACR). LC-MS was used to investigate the key fragmentation steps and kinetic properties of the ACR. Atomic force microscopy (AFM), fluorescence techniques and circular dichroism (CD) spectroscopy were applied to study the structural polymorphism and conformational changes that can precede or occur with autohydrolytic reaction mixtures of A β _{14–24} containing peptides and A β _{1–40/42}. Our findings establish the autohydrolytic behavior of A β _{14/16–24/25} congeners and their potential for cross-seeding (of self-templating) cascade hydrolysis in larger A β isoforms. In various aggregation states with diverse secondary structure, A β congeners can become susceptible to cascade hydrolysis by changes in the environment and through cross-seeding catalysis of autohydrolytic active fragment compositions.

Results

Peptide substrates and initial catalysis screenings

Quenched fluorescence resonance energy transfer (FRET) substrates containing 3-nitrotyrosine (Y(NO₂) or Y*) and 2-aminobenzoic amide (Abz) have previously been used to monitor the progress of enzymatic peptide hydrolysis by the increase of fluorescence intensity (I_F) with progressing peptide cleavage.³⁹ During initial studies of combinatorial catalyst libraries for putative Pd-assisted hydrolysis, the A β _{14–24} congener Abz-Pra-[HQKLFFFAEDV]-Y(NO₂)G (**1a**) was synthesized by Fmoc-based solid-phase peptide synthesis (SPPS) and characterized by LC-MS (Fig. S1†). As is well documented for A β congeners aggregation states depend strongly on the mode of preparation of stock solutions.^{16,40} This became obvious during incubation of solutions




Fig. 1 Synthesized A β peptide sequences and their autohydrolytic self-fragmentation pattern. Color coded amino acid sequence of A β _{1–28} is presented for the extended A β _{14–24} nucleation site (blue (+); orange, H-bonding and polar; green, hydrophobic; red, acidic (–)). Blue arrows indicate primary scissile bonds. Horizontal arrows indicate cleavage fragments (f0–f6) and f0*–f4*. The f7*/f7-scissile bond represents an autohydrolysis pathway distinct from f0-relayed-processing.

of the FRET substrate **1a** at 37 °C for up to 180 h. The observed dynamic changes in I_F were complex and varied with pH, ionic strength, and temperature. Surprisingly, some samples with increased I_F did not show the expected substrate cleavage, rather it reflected changes in aggregation states. Upon ten-fold dilution in 70% acetonitrile/water, the substrate eventually hydrolysed while the undiluted samples remained intact (Fig. S2A†). The hydrolysis experiments with **1a** were repeated several times under slightly varied conditions with the same result of delay and specificity of cleavage also upon dilution in water in the absence of a palladium catalyst (Fig. S2C†). These results indicated that we were observing an autohydrolytic cascade reaction (ACR), inherent to short Alzheimer's A β -derived peptides (Fig. 1). To investigate the formation of the proteolytically active peptide self-assemblies, we, in addition to **1a**, synthesized amyloidogenic peptide **2** (Bz-Pra-[HQKLFFFAEDV]-YG), the natural sequence homologue A β _{12–25}-Gly-OH (**3**), D-amino acid analogue **4** and acquired A β _{1–28} (**5**) as well as A β _{1–40/42} (**6** & **7**) (Table 1). We also synthesized **1b**, **1c** and **1d** as permutations of **1a** as well as selected their autocatalytic fragments for ACR experiments (Fig. S1 and S3A†).

A β _{14–24} congeners are susceptible to intrinsic autohydrolysis

To ensure that hydrolysis was neither due to proteases or microbial contamination, experiments were conducted in sterilized Milli-Q water in the presence of sodium azide and a protease inhibitor cocktail. We observed autohydrolytic cascade of **1a–3** with a common fragment fingerprint (Fig. 1, 2B and S3–S6†), which was reproducible under a variety of experimental conditions (Tables 2, S1 and S2†). This result indicated that the unnatural modifications in peptide **1a** (Abz/Y*) and **2** (Bz/Y) were not pivotal for the autocatalysis. The initial step of the ACR in A β _{14–24} congeners **1–3** was the endoproteolytic cleavage between Gln₁₅ and Lys₁₆ as well as at the natural α -secretase cleavage site Lys₁₆–Leu₁₇ (Fig. 1, 2A and C). However, the specificity seemed to be quite promiscuous and initial cleavage was followed by several steps of aminopeptidase-like relay processing of C-terminal



Table 1 Annotation for presented A β peptide congeners^a

Peptide	A β sequence	f0 fragment ^b	f0 sequence
1a-d ^{c,d}	Abz-Pra-[A β ₁₄₋₂₄]-Y*G	[A β ₁₆₋₂₄]-Y*G	KLVFFAEDVY*G
2	Bz-Pra-[A β ₁₄₋₂₄]-YG	[A β ₁₆₋₂₄]-YG	KLVFFAEDVYGG
3	[A β ₁₂₋₂₅]-G	[A β ₁₆₋₂₅]-G	KLVFFAEDVGG
4 ^e	[A β ₁₂₋₂₅]-G	[A β ₁₆₋₂₅]-G	KLVFFAEDVGG
5	A β ₁₋₂₈	A β ₁₆₋₂₈	KLVFFAEDVGSNK
6	A β ₁₋₄₀	A β ₁₆₋₄₀	KLVFFAEDVGSNK-GAIIGLMVGGVV
7	A β ₁₋₄₂	A β ₁₆₋₄₂	KLVFFAEDVGSNK-GAIIGLMVGGVVIA

^a Abbreviations: Abz, 2-aminobenzoyl; Pra, propargylglycine (for peptide immobilization); Y*, Tyr(3-NO₂); Bz, benzoyl. ^b Primary autocleavage fragment of the A β -ACR. ^c A β peptides with additional C-terminal nitro-tyrosine and glycine. ^d Derivatives to test the influence of termini and lysine: **1a** = C-terminal acid; **1b** = **1a** (Lys₁₆(Tfa)), **1c** = **1a** (C-terminal propylamide) and **1d** = **1a** (C-terminal 2-ethanol amide). ^e D-Amino acid peptides.

fragments f0 and f1 (A β _{16/17-24} congeners in Fig. 1) along the hydrophobic core-sequence A β ₁₇₋₂₁ toward fragment f4 (A β ₂₀₋₂₄ congener) and a final processing towards fragment f6 for peptides **1a-1d** (Fig. 2B and S6A-C[†]).

The N-terminal fragments (R₁: peptide) R₁-HQKL (f2*) and R₁-HQKLVF (f4*) were reproducibly detected both in ACR assays with peptides **1a** and **2** (Fig. 2B-E and S7C[†]) as well as with A β ₁₋₂₈

(Fig. S16[†]) and A β ₁₋₄₀. This result suggests a second pathway for primary endoproteolytic cleavage which generates the corresponding C-terminal fragments [A β ₁₈₋₂₄]-R₂ (f2) and fragment [A β ₂₀₋₂₄]-R₂ (f4) independently from the f1 → f4 aminopeptidase-like processing route (Fig. 1). The increase of f4*/f4 cleavage was accompanied by progressive disappearance of the f2* fragment and increase of the f0* fragment (Fig. 2E). This result suggests an autocatalytic carboxypeptidase-like reaction pathway of f4* → f0* (R₁-HQKLVF → R₁-HQ) processing. In addition, the N-terminal f0*-fragment (R₁-HQ) is prone to subsequent carboxypeptidase-like processing toward R₁ (fragments f8* and f9* in Fig. 1, for LC-MS analysis see ESI Fig. S3D, E, S16, S17B and F[†]). The identity of cleavage fragments was confirmed by their high-resolution mass spectra and MS/MS sequencing (Fig. 2D and S4[†]). Derived from hydrolysis samples of peptides **1a** and **2**, MS/MS sequencing of the primary autocleavage fragment f0 (*m/z* = 666.8262⁺ and *m/z* = 644.3182⁺, respectively) confirmed the identity of the respective C-terminal fragment sequence [A β ₁₆₋₂₄]-Y*G (Fig. S7D and F[†]). This result is consistent with the primary scissile bond Gln₁₅-Lys₁₆ observed in autoproteolysis of A β ₁₋₄₂ oligomers, as previously reported by Rudinskiy *et al.*³⁴

Influence of environmental parameters on A β -ACR

Autohydrolysis samples showed a lag-phase, followed by a period with rapidly increased hydrolytic activity (Fig. 2A-C and E). However, the times of the onset of catalysis and rate of




Fig. 2 Autoprocessing of truncated A β -peptides. LC-MS chromatograms presenting autohydrolysis of A β ₁₄₋₂₄ congeners **1a**, **2** and **3** with the assignment of cleavage fragments. (A) Hydrolysis kinetics for **1a** upon dilution of reaction stock (Table 2, entry 1 and Fig. S7A[†]) over 7 d at 37 °C: cyan, green and orange (MS-TIC); blue (UV-250 nm); magenta (UV-275 nm). Repeat experiments are presented in Fig. S7B and G. [†] (B) LC-MS monitoring of the ACR upon 1 : 4.5 dilution of reaction stock solutions (dotted traces, conditions Table 2, entry 2) of **1a**, **2** and **3**, respectively, after 6 d at 20 °C. Blue traces (UV-250 nm) and red traces (MS-TIC) represent fragmentation (as annotated) after 9 d. Repeat samples are presented in Fig. S9A, B and E. [†] (C) Hydrolysis upon 1 : 4.5 dilution of aged aggregated samples (Table 2, entry 3 and Table S1, [†] stock entry XIX) at 20 °C indicated that disaggregation correlates with the onset of the ACR: green, red and light blue traces (MS-TIC), black (UV-214 nm) and blue (UV-250 nm) traces are stacked according to the time of acquisition. (D) Identification of ACR cleavage fragments by MS with annotation of the fragment sequences. (E) Independent 24 d kinetics of the autohydrolysis of peptide **2** (Table 2, entry 4). The kinetic analysis is presented in Fig. S8[†](see also repeat reactions in Fig. S7C and E[†]).



Table 2 Conditional kinetic behaviour of A β ACR-hydrolysis^{a,b}

Entry	Peptide	[A]/ μ M	[B]/mM	pH	% DMSO	$t_{(37)}/d$	$t_{(20)}/d$	^b ₃₇ °C	^b ₂₀ °C	t_{lag}/h	$t^{1/2}/h$	Figure ref
1	1a	165	10	7.6	3.2	14	0	++ ^c	na	60	66	Fig. 2A
2 ^d	1a, 2, 3	100–117	10	7.6	5	28	9	—	++	160	36–54	Fig. 2B
3 ^d	2	55	10	7.6	0	7	16	—	+	48	60	Fig. 2C
4	2	100	5	7.6	5	24	0	+++	na	192	60	Fig. 2E
5	f0(1a)	50	0.9	7.6	0	1	20	—	+++	216	76	Fig. 3A
6 ^e	A β_{1-28} /f0(1a)	30/8	10	7.6	0	0	18	na	+++	72	60	Fig. 3B
7 ^d	3	60	10	7.6	0	7	16	—	++	92	36	Fig. 4A
8 ^d	2	120	5	7.6	3.7	7	7	+	++	140	na	Fig. 4C
9	f0(1a)	110	10	7.4	0	14	0	++	na	140	na	Fig. 4H
10	1a /f0	45/12	10	7.4	0	16	10	+	++	200	na	Fig. 4I
11	A β_{1-40} /f0(1a)	30/5	10	7.33	0	12	12	+++	+++	120	na	Fig. 5A

^a [A] or [A]/[f0]: concentrations of the parent peptide (and f0-seed) in reaction stock solutions; [B]: buffer concentration (PB); $t_{(37)}$: primary incubation time at 37 °C; $t_{(20)}$: secondary incubation time at 20 °C. ^b Extent of hydrolysis: (+++) >95%, (++) 40–95%, (+) 20–40%, and (–) 0%. na not applicable. t_{lag} : latency for detected onset of the ACR. The half-life $t^{1/2}$ is the average value estimated from several experiments (Table S2). ^c Conditions: ACR progress upon 1 : 4.5 downstream dilution and continuous incubation at 37 °C. ^d Conditions: spontaneous ACR of **1a–3** at 20 °C upon 1 : 4.5 dilution of preincubated reaction stock solutions with water. ^e f0(**1a**) cross-seeding ACR in A β_{1-28} after 4 days at 20 °C.

autohydrolysis were condition-dependent (Table 2) and particularly influenced by the stock recipe and co-solvent content (Tables S1 and S2[†]). At 37 °C, the onset for the ACR occurred with $t_{lag} = 180–240$ h and an approximate $t^{1/2}$ (f1 \rightarrow f4/f6) of 48–72 h (Fig. 2E, S7C and E[†]). Surprisingly, dilution and subsequent incubation at 20–22 °C increased rates to a $t^{1/2}$ of 20–48 h for the conversion of the starting material (Table S2 and Fig. S9[†]). Samples of **1a** (100 μ M) and **2** (158 μ M) containing 1.7–3.2 vol% DMSO (stock conditions in Table S1, [†] entry III) showed 15–40% selective accumulation of f0-fragment KLVFFAEDVY*G at 37 °C over 7 d (Fig. S7A[†]), which only continued towards autohydrolysis fragments f1/f4 upon sample dilution in Milli-Q water (Fig. 2A). Stock solutions of **1a**, **2** and **3** in 0.2% 0.1 M NaOH/DMSO, diluted (1 : 20) in phosphate buffer (PB) to 5% final DMSO, did not provide onset of the ACR after 4–5 weeks of incubation at 37 °C. However, all samples of **1a**, **2** and **3** being subsequently further diluted 1 : 4.5 in Milli-Q water showed

a spontaneous ACR at 20 °C with a common fragment fingerprint after 6–9 days (Fig. 2B and S9A–D[†]). Similar samples prepared after 2 days from the same stock to 5% DMSO also hydrolysed at 37 °C with a lag-phase of 8 d (Table 2, entry 4 and Fig. 2E) indicating changes in this stock. A spontaneous ACR also occurred upon longer periods of incubation in undiluted samples at 20 °C (Fig. S6A[†]). Peptide **2** disaggregated upon 1 : 4.5 downstream dilution as indicated by increased intensity in the LC-UV-trace and presented f1 fragment release and onset of the ACR within 4 days at 20 °C (Fig. 2C). This was observed under a variety of conditions with all A β_{14-24} congeners, **1a–3**, showing similar lag-times of 48–60 h and conversion to f4 with a $t^{1/2}$ of 20–48 h (Fig. 4A and S9A–E[†]). At 37 °C, the aminopeptidase- and carboxypeptidase-like activity following initial endoproteolytic cleavages has a $t^{1/2}$ of \sim 48 h producing mainly f4 and f0* as end products (Fig. 2E and S8[†]).




Fig. 3 Kinetics of f0-ACR and of cross-seeding with f0(**1a**) to A β_{1-28} . (A) Autohydrolysis of f0(**1a**) (Table 2, entry 5 and Table S1, [†] stock entry XII) was monitored by LC-MS after 9 d at 20 °C followed by 1 d at 37 °C: black traces (UV-275 nm) and colored traces (MS-TIC). (B) Cross-seeding analysis with autohydrolytic assemblies of f0(**1a**) (Fig. S10B[†]) that unlock quantitative self-processing in A β_{1-28} at 20 °C (conditions Table 2, entry 6): black traces (UV-214 nm) and colored traces (MS-TIC). Repeat experiments are presented in Fig. S15A, D and E. [†] (C) Kinetic plot (UV-275 nm) of integral intensities for data in (A), and (D) kinetic plot (UV-214 nm) of integral intensities for data in (B) showing both the lag time and rate of A β_{1-28} hydrolysis by cross seeding.



A β_{16-24} congeners possess intrinsic autohydrolytic properties

To further elucidate the nature of the ACR, we investigated the autohydrolytic properties of the synthesized primary autocleavage fragment KLVFFAEDVY*G (f0) of peptide **1a** (Table 1). In a series of experiments, we reproducibly observed f0 \rightarrow f4 \rightarrow f6 autoprocessing (Fig. 3A), under a variety of conditions at 20 °C as well as 37 °C (Fig. S10 and S25B \dagger). A half time $t^{1/2}$ of 70–76 h was observed for the cleavage steps in the autoprocessing at 20 °C (Fig. 3C). Furthermore, processing to f1 showed a different kinetic behaviour than that to f4. Once the autohydrolytic complex of f0(**1a**) formed a catalytic seed ($t_{\text{lag}} = 7\text{--}11$ d), f0 converted initially to f1, followed by relay-processing to f4/f6 (Fig. 3C), suggesting that truncated fragments contribute significantly to the autocatalysis. Irrespective of changes in the conditions (concentration, pH, and T), repeat experiments showed similar half-times $t^{1/2}$ of 48–84 h for f0 \rightarrow f1 primary cleavage (Fig. S11 \dagger) and further autoprocessing with a $t^{1/2}$ (f4) of 30–72 h after an initial t_{lag} of 100–200 h (Fig. S10 \dagger). To clarify on the intrinsic nature of autohydrolysis in A β_{16-24} congeners, we performed ACR screening assays using the D-amino acid analog **4** of L-peptide **3** ([A β_{12-25}]-Gly, vhhqklvffaedvgg) and the respective f0 fragment [A β_{16-25}]-Gly (Fig. S12–S14 \dagger). Working without a co-solvent afforded autohydrolysis samples of f0 with 10–60% conversion toward the f2 fragment after 9–15 d at 37 °C (Fig. S13 \dagger). The stability and conditional fluctuation in aggregation states influenced the rate of hydrolysis of **4** even in the presence of traces of f0(**4**) resulting in rather slow hydrolysis that eventually provided the f4 fragment (Fig. S14D \dagger) over a prolonged period. After 22 weeks, the f0 fragment showed complete conversion towards f1, f3 and f4 fragments as well as the truncated C-terminal A β_{19-25} fragment (Fig. S14A and E \dagger).

Cross-catalytic ACR seeding in A β_{1-28}

To discern the cross-catalytic ability of the f0 fragment, we investigated seeding the ACR in A β_{1-28} with [A β_{16-24}]-Y*G (f0(**1a**)). We screened several stock solutions of f0(**1a**) (100–300 μM and pH 7.6–8.2) for subsequent ACR activation (Table S1, \dagger stock entries VIII & XII) upon dilution (pH 7.4–7.8). When f0(**1a**) was pre-activated separately in that way (Fig. 3A and S10 \dagger), cross-seeding into samples of A β_{1-28} induced the onset of autohydrolysis within 3–5 d at 20 °C (Fig. 3B and S15A, D and E(iii) \dagger). The observed half-life ($t^{1/2} \sim 76$ h) for template-directed f0*/f0 autocleavage of A β_{1-28} (Fig. 3D) was similar to that of several independent repeat samples only containing f0(**1a**) (Fig. S10, S11B and C \dagger). Repeat experiments for f0-cross-seeding catalysis showed enhanced reaction rates ($t^{1/2} < 24$ h) after preincubation at 37 °C and afforded further A β_{1-28} autoprocessing toward fragments f9*, f2 and f3 at 20 °C (Fig. S15A–C and S16 \dagger). Negative controls with no activated f0-cross-seeding remained intact (as shown in LC-MS (i) and (iv) in Fig. S15D \dagger). Independent of catalyst addition, A β_{1-28} showed intrinsic autohydrolysis fragments A $\beta_{1-24/25}$ as well as A β_{1-26} and A $\beta_{18/20-26}$ next to A β_{1-16} (f1*) or A $\beta_{1-15/17}$ (f0*/f2*) (see ESI Fig. S15E, S17B, C and F \dagger). Both experiments confirmed f0*/f0 (Gln₁₅-Lys₁₆), f1*/f1, f2*/f2 and f4*/f4 (Phe₁₉-Phe₂₀) as intrinsic scissile bonds in assembly-driven autohydrolysis of A β_{1-28} (Fig. 1

and S16 \dagger), which is in agreement with observations by Rudinskiy *et al.* for autoproteolysis of A β_{1-42} .³⁴

Aggregation and structural behaviour of A β_{14-24} peptides in relation to their autohydrolysis

The fluorogenic properties of **1a** allowed for qualitative monitoring of structural changes in the aggregation process that could associate with the onset and progression of the ACR (Fig. S18A and E). To elucidate further on the possible relation between β -sheet self-assembly and the occurrence of autohydrolysis fragments, we screened **1a**, **2** and **3** under different stock solvent and buffer conditions *via* Thioflavin T (ThT) aggregation assay.⁴¹ To confirm largely monomeric (unstructured) starting conditions for a set of repeat reactions, CD (Fig. S18C and 25D \dagger) and dynamic light scattering (DLS) studies were performed on diluted stock aliquots (Fig. S19 \dagger).⁴⁰ Fibril formation was most prominent with **3** (Fig. S20A and D \dagger), but also occurred in **2** and **1a** (Fig. S18B, S21A and S22A \dagger), which is in agreement with previous reports on the aggregation behaviour of similar A β peptides.^{42,43} Fibrillation samples of **3** remained stable at 37 °C but showed f0-autocleavage after prolonged incubation at 20 °C (Fig. S20B \dagger). Furthermore, several independent fibrillation assays provided ThT-positive samples that did show accelerated downstream autohydrolysis at 20 °C upon dilution (Fig. S18D, S20E and F \dagger).

During screenings for autohydrolysis, we observed a pattern of aggregation in diluted LC-MS samples at 20 °C, with the disappearance of the LC-UV trace (Fig. 4A, day 2). In the subsequent LC-MS analysis, a pronounced LC-UV signal reappeared indicating the disaggregation, fragment release and ACR of f1 to f4 within 2–4 days. This was consistent with spontaneous higher-order amyloid aggregation upon dilution and subsequent reorganization into more soluble amyloid self-assemblies may accompany the ACR in A β_{14-24} congeners (Fig. S9D and F \dagger). We applied AFM to study the possible morphologies of insoluble aggregates that could relate to the loss of the UV-absorbance signal in the LC-MS chromatogram (Fig. S23 \dagger). Incubation samples of **1a** showed different sized lumps, granules and biomolecular condensate or coacervate structures upon the disappearance of the UV-signal (Fig. S23A–C and S24 \dagger). Upon dilution, wet samples of peptide **2** (Fig. 4B and C) showed spherical-shaped oligomers (0.8 \pm 0.4 nm average height, Fig. 4D) and molten granules (1.06 \pm 0.36 nm average height, Fig. 4F) at different stages of autohydrolysis by AFM. The abundance and size distribution of these aggregates changed over time and presented bundled fibrils next to larger spherulites (2.4 \pm 0.7 average height) in the least reactive sample (Fig. 4B and E), while at higher dilution (Fig. 4C) AFM of the particles was consistent with that of flattened spherical structures (1.65 \pm 0.75 nm average height and 7–18 nm wide). This result indicated dynamic changes of globular aggregates and spontaneous fibril formation can coexist in autohydrolytic amyloid assembly. Furthermore, the identified f3* fragment Bz-Pra-HQKLV ($m/z = 412.23(2+)$) confirmed carboxypeptidase-like activity in the ACR from f4* to f0* (Fig. 4C).

A variety of repeat experiments with Pd and Cu as trace metals showed no direct correlation with the onset of the ACR (*e.g.* Fig. S17A–D, S20A, B, S22F and S25C \dagger). Furthermore, Inductively






Fig. 4 Aggregation behaviour and structural properties of autohydrolytic $A\beta_{14-24}$ peptides. (A) Stacked LC-MS (colored traces (MS-TIC), black traces (UV-214 nm)) of peptide 3 (stock entry XIX, Table S1†) upon 1 : 4.5 dilution after 23 d (see entry 7, Table 2 and Fig. S20A and F†). (B) LC-MS spectra of peptide 2 (for conditions see entry 8, Table 2 and S1,† stock entry V) were recorded 7 days after 1 : 2 dilution at 20 °C subsequent to 7 days incubation at 37 °C. (C) LC-MS of a duplicate sample at 1 : 4 dilution. (D) AFM image (black bar represents 200 nm) of a hydrolysis sample (B). The white square inset shows 5-fold magnification. (E) AFM image after 4 additional days shows enlarged aggregates and fibrils (black bar, 200 nm). (F) AFM image (black bar, 200 nm) of the hydrolysis sample (C) shows depletion of aggregates by hydrolysis of the sample in (G) after 4 additional days (black bar, 200 nm). (H) CD spectra of f0(1a) (Table 2, entry 9) upon 13 d at 37 °C (ACR onset on day 5, see Fig. S10D–F† and for repeat experiments see Fig. S25A and B†). (I) Transformation of the 1a random coil structure (Table 2, entry 10) to β -sheets over 13 d upon seeding with f0(1a) (ACR observed after \sim 10 d at 37 °C, for LC-MS see Fig. S25H†). (J) CD of 1a (50 μ M, 7 d at 37 °C) before (red) and after (blue dotted) seeding with f0(1a) (20 μ M). CD of 1a (green) and 1a + f0(1a) (blue) show β -sheets after 28 d at 37 °C (for cross-seeding repeat experiments see Fig. S25D and G†). All samples showed the same fragment fingerprint with 30–60% turn-over (Fig. S25C†).

Coupled Plasma-Mass Spectrometry (ICP-MS) analysis of selected buffers and of autohydrolytically active samples indicated only low concentrations of metal ions (Cr, Ni, Cu, Zn, and Pd). With added EDTA (50–220 μ M), we observed f0-primary autocleavage (Fig. S20B†) and successive cascade hydrolysis over a prolonged period of time (Fig. S22D†) as well as upon f0(1a) cross-seeding to $A\beta_{1-28}$ (Fig. S26E and F†). These results suggest that metallated species do not play a major role in the ACR as outlined in the ESI.† However, the metal binding chelate ligand EDTA showed an inhibitory effect on the ACR at 10–200 μ M (Fig. S9E†). Occasionally, we observed moderate autocleavage between Glu₂₃ and Val₂₄ (fragment R1–HQKLVFFAED (f7*), Fig. 1 and S2B†), correlating with β -sheet formation, particularly in the presence of high concentrations of Cu(II) and EDTA, at pH 7.8–8.0 of peptide 1a, 1d and 2 (Fig. S21 and S22A–C†), which confirms previous reports by others observing $A\beta_{1-23}$ from autohydrolysis of $A\beta_{1-40}$ and $A\beta_{1-42}$ in the early aggregation phase.^{33,34}

Conformational transitions accompanying autohydrolytically active amyloid assemblies of $A\beta_{14-24}$ congener 1a

The autohydrolysis presented here raised the question whether the progression of the ACR coincides with conformational changes? Conformational transitions were investigated for 1a during autohydrolysis at 37 °C, both with and without seeding

with f0(1a). 1a showed enhanced solubility and increased conformational dynamics as compared to the native analog [$A\beta_{12-25}$]-G (3). CD of f0(1a) showed enrichment of β -sheet conformation in aqueous buffer at pH 7.1–7.8 (Fig. 4H). Despite the caveat that the unnatural side-chains may influence the CD simulations, secondary structure analysis was performed with the methods Dichroweb CDSSTR and Bestsel,^{44–46} suggesting extended structures, dominated by β -sheets and turns with a transient appearance of α -helical structures during the f0 \rightarrow f1 \rightarrow f2 processing. Seeding with β -sheet-rich f0(1a) on freshly prepared or preincubated solution of disordered peptide 1a induced a slow conformational shift toward β -sheet dominated assemblies (Fig. 4I and J), which was accompanied by subsequent progression of autohydrolysis over the course of 2–4 weeks (Fig. S25C, G and H†). This result indicated the potential of f0(1a) for structural influence on 1a by cross-seeding. However, due to the favorable properties of 1a, the ACR was also observed within 2–3 weeks starting from disordered 1a at 37 °C as well as 20 °C (Fig. S6A and S25D–F†). The actual ACR of 1a seemed to show no main conformational assembly preference for catalysis by 1a and f0(1a), and catalysis rather depends on minor populations of structured active clusters not detectable by CD. Thus, a structurally distinct population of peptides is not a prerequisite for the ACR. The selectivity of the fragmentation reaction suggests that well-structured peptide






Fig. 5 Cross-seeding autohydrolysis in $A\beta_{1-40}$ and characterisation of aggregation states. (A) Stacked LC-MS (colored traces (MS-TIC), black traces (UV-214–320 nm)) of $A\beta_{1-40}$ (30 μM) replicates PB (10 mM) with 0.02 w% NaN_3 and protease inhibitor (*) at pH 7.33 after 12 d at 25 °C (i) & (iii) and 12 d at 37 °C (ii) & (iv). Samples (iii) and (iv) received additional f0(1a) cross-seeding (Table S2, † stock entry XII and Fig. S26B(ii)†) upon initial sample preparation. f0(1a)-seeded samples (ii) and (iii) showed full degradation of $A\beta_{1-40}$ with the common ACR fragment fingerprint (f0*/f2*/f4* and f2/f4) (Fig. S32†) including a variety of truncated isoforms such as $A\beta_{12-18}$ ($m/z = 859.457(1+)$), $A\beta_{20-33}$ ($m/z = 689.264(2+)$), $A\beta_{20-34}$ ($m/z = 745.899(2+)$) and $A\beta_{22-34}$ ($m/z = 636.845(2+)$) (Fig. S30 and S33†). High-resolution mass analysis with a list of the main fragments identified in these mixtures are presented in Fig. S29, 30 and S34.† (B) AFM images after drying of the wet mica surface upon exposure to the sample (iv) (black bar, 200 nm). Right panel shows a zoomed-in image of ring-shaped oligomers. (C) AFM images after drying of the mica exposed to sample (ii) (black bar, 200 nm). Right panel shows zoomed-in images of ring-shaped oligomers next to fibrils.

assemblies are key to the autohydrolytic process, showing the ability to self-replicate from the precursor peptides.

Cascade autohydrolysis of $A\beta_{1-40/42}$

To confirm that self-templating autohydrolysis at the nucleation site is a general property of $A\beta$ peptides, we performed cross-seeding experiments with activated assemblies of the f0(1a) fragment on $A\beta_{1-40}$ (20–30 μM). Several repeat experiments showed autohydrolysis with the typical ACR fragment fingerprint (f9*/f0*/f2*/f4*) and $A\beta_{16-40}$ (f0) \rightarrow $A\beta_{22-40}$ (f6) upon seeding (Fig. 5A and S28–S34†). In addition, we observed a variety of terminally truncated isoforms of these fragments *e.g.* $A\beta_{12-28}$, $A\beta_{20-27}$, $A\beta_{20-34}$ and its terminally truncated congeners (Fig. S30†). However, $A\beta_{1-40}$ also showed the ACR with the common fragment fingerprint under various conditions without active fragment cross-seeding (Fig. S27, S28A and S29†). Nonetheless, the substoichiometric addition of f0/f1/f4(1a) (15–30 mol%) to aggregation samples of $A\beta_{1-40}$ did neither inhibit nor decrease its fibrillation in the ThT assay at 37 °C (Fig. S31A and B†). However, fragment-seeded ThT-fibrillation samples showed a notable number of autocleavage fragments f0*/f2* already after 3 days of incubation (with periodic agitation), while ThT-containing controls without seeding remained intact (Fig. S31C–E†). This result confirmed that the ACR and fibril formation can coexist as confirmed by AFM imaging (Fig. S28B, C and S31F†). The hydrolysis of ACR-seeded fibrillation samples proceeded at 20 °C over the course of 6 days showing fragments f0/f1/f2/f3/f4 but notably $A\beta_{20-27}$ among other truncated $A\beta$ fragment isoforms (Fig. S28 and S31C–E†).

In parallel, we used AFM imaging to investigate the aggregate morphologies of autohydrolytic active samples incubated without ThT and no periodic agitation. Compared to ThT-fibrillation samples, we observed a lower abundance of fibrils in these samples but also a variety of spherical particles as well as ring-segmented oligomers and annular protofibrils with a discrete size distribution (20–80 nm in diameter) in both non-hydrolytic and ACR-active samples (Fig. 5B and S27D†). This

result is consistent with previous reports on the appearance ring-shaped oligomers and annular aggregates in $A\beta_{1-40}$ self-assembly.^{47–49}

Preincubation at 25 °C (5–9 d) followed by incubation at 37 °C repeatedly provided autohydrolytic active samples of $A\beta_{1-40}$ that showed ring-shaped structures, particles and amorphous aggregates besides fibrils (Fig. S27D and S28†). This result suggests that the initial conditions favoring oligomer formation at 25 °C over fibril nucleation/elongation (37 °C)^{16,48,50} do increase the probability for inducing the ACR in $A\beta_{1-40}$ (Fig. S27A†). Assays with $A\beta_{1-42}$ were more challenging due to its increased aggregation propensity in phosphate buffer. However, preincubation at 25 °C followed by f0-cross-seeding and incubation at 37 °C provided notable autocleavage after 14 d at 37 °C with increased autohydrolytic activity as compared to non-seeded replicates (Fig. S35D and S37†). Upon dilution $A\beta_{1-42}$ fibrils with added ThT and f0(1a)-seed solution showed gradual f9*/f0*/f2* autocleavage after 3–4 weeks of incubation at 25 °C (Fig. S35A–C and S36†). These results confirmed that cross-seeding catalysis can unlock autohydrolysis in complex aggregation mixtures of full-length $A\beta_{1-42}$. As the peptide solubility is critical for the formation of ACR active oligomers/aggregates, the extent of fibrillation is in balance with the ACR and may account for the differences observed between the $A\beta_{1-42}$, $A\beta_{1-40}$ and $A\beta_{1-28}$ autohydrolysis.

Discussion

We demonstrated that assemblies of truncated $A\beta$ peptides, containing the extended nucleation sequence $A\beta_{14-24}$ (HQKLVFFAEDV) possess intrinsic and specific autohydrolytic properties. The autocleavage fragment fingerprint (Fig. 1) recurred under a broad spectrum of conditions (Table S2†). The results show that primary C-terminal cleavage fragments f0/f1 as well as f4, derived through endoproteolytic activity in $A\beta_{14-24}$ congeners, are in turn autohydrolytically active components within an autocatalytic reaction network that extends to aminopeptidase-like processing along the $A\beta$ nucleation site



An important conclusion is that there always exists a balance between the extend of precipitation and the formation of proteolytic A β . This could explain the release and the slow processing observed in concentrated samples and in plaques *in vivo*. The present work proposes a mechanistic model for self-propagating autohydrolysis in A β aggregates. Assemblies of A β autocleavage fragments may function as neurotoxins through their proteolytic properties or membrane-disrupting pore formation. Their environment controlled self-degradation could also present an opportunity to intercept A β neurotoxicity and plaque formation. Future characterization of transient, highly dynamic aggregation states is a complex affair and will require powerful analytical tools to identify key species that facilitate cascade hydrolysis. Exhaustive mutation studies on various A β congeners may elucidate critical residues in autohydrolytic active-site formation. In perspective, autohydrolytic peptide self-assembly could furthermore provide new insight into the emerging field of systems chemistry.^{51,57,60,74–80}

Data availability

All additional data are in the ESI† associated with this publication.

Author contributions

M. Wolfram and M. Meldal conceived the project, M. Wolfram and M. Meldal synthesized all compounds, T. Hassenkam performed the AFM studies, M. Wolfram performed hydrolysis studies and CD, DLS and ThT assays, M. Wolfram and M. Meldal performed LC-MS analysis, M. Wolfram and M. Li performed MS-MS analysis, all co-authors contributed to the collective data analysis and conclusions on results, M. Wolfram, M. K. Tiwari and M. Meldal drafted the manuscript and all co-authors contributed to reviewing and editing the manuscript into its final format.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We are grateful to Lars Øgdenal for DLS assistance, to David Teze, Sophia Häfner, Lars Hemmingsen and Sanne Schoffelen for discussions, to Theis-Brock Nannenstad for MS assistance, to Peter W. Thulstrup for access to a CD instrument and to Afra Fekri, Adrian Schiefler and Christian Koefod for LC-MS support. The Lundbeck Foundation (R95-2012-9008 to MW and R231-2016-3276 to MKT), DFF (DFF-4005-00082 to MJB and MKT), VILLUM FONDEN (00028295 to MW) and UCPH (CECB – Lighthouse grant) are gratefully acknowledged for their financial support.

Notes and references

1 H. Neurath, *Science*, 1984, **224**, 350–357.

- W. E. Balch, R. I. Morimoto, A. Dillin and J. W. Kelly, *Science*, 2008, **319**, 916–919.
- J.-P. Colletier, A. Laganowsky, M. Landau, M. Zhao, A. B. Soriaga, L. Goldschmidt, D. Flot, D. Cascio, M. R. Sawaya and D. Eisenberg, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 16938–16943.
- M. Jucker and L. C. Walker, *Nature*, 2013, **501**, 45–51.
- T. P. J. Knowles, M. Vendruscolo and C. M. Dobson, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 384–396.
- R. Riek and D. S. Eisenberg, *Nature*, 2016, **539**, 227.
- M. P. Lambert, A. K. Barlow, B. A. Chromy, C. Edwards, R. Freed, M. Liosatos, T. E. Morgan, I. Rozovsky, B. Trommer, K. L. Viola, P. Wals, C. Zhang, C. E. Finch, G. A. Krafft and W. L. Klein, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 6448–6453.
- D. M. Hartley, D. M. Walsh, C. P. Ye, T. Diehl, S. Vasquez, P. M. Vassilev, D. B. Teplow and D. J. Selkoe, *J. Neurosci.*, 1999, **19**, 8876–8884.
- M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J. Zurdo, N. Taddei, G. Ramponi, C. M. Dobson and M. Stefani, *Nature*, 2002, **416**, 507–511.
- R. Kaye, E. Head, J. L. Thompson, T. M. McIntire, S. C. Milton, C. W. Cotman and C. G. Glabe, *Science*, 2003, **300**, 486–489.
- C. Haass and D. J. Selkoe, *Nat. Rev. Mol. Cell Biol.*, 2007, **8**, 101–112.
- E. Y. Hayden and D. B. Teplow, *Alzheimer's Res. Ther.*, 2013, **5**, 60.
- E. N. Cline, M. A. Bicca, K. L. Viola and W. L. Klein, *J. Alzheimer's Dis.*, 2018, **64**, S567–s610.
- M. Hoshi, M. Sato, S. Matsumoto, A. Noguchi, K. Yasutake, N. Yoshida and K. Sato, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 6370–6375.
- S. Barghorn, V. Nimmrich, A. Striebinger, C. Krantz, P. Keller, B. Janson, M. Bahr, M. Schmidt, R. S. Bitner, J. Harlan, E. Barlow, U. Ebert and H. Hillen, *J. Neurochem.*, 2005, **95**, 834–847.
- M. Necula, R. Kaye, S. Milton and C. G. Glabe, *J. Biol. Chem.*, 2007, **282**, 10311–10324.
- S. Matsumura, K. Shinoda, M. Yamada, S. Yokojima, M. Inoue, T. Ohnishi, T. Shimada, K. Kikuchi, D. Masui, S. Hashimoto, M. Sato, A. Ito, M. Akioka, S. Takagi, Y. Nakamura, K. Nemoto, Y. Hasegawa, H. Takamoto, H. Inoue, S. Nakamura, Y.-i. Nabeshima, D. B. Teplow, M. Kinjo and M. Hoshi, *J. Biol. Chem.*, 2011, **286**, 11555–11562.
- F. Hasecke, T. Miti, C. Perez, J. Barton, D. Schölzel, L. Gremer, C. S. R. Grüning, G. Matthews, G. Meisl, T. P. J. Knowles, D. Willbold, P. Neudecker, H. Heise, G. Ullah, W. Hoyer and M. Muschol, *Chem. Sci.*, 2018, **9**, 5937–5948.
- C. H. van Dyck, *Biol. Psychiatry*, 2018, **83**, 311–319.
- N. M. Milović, J. D. Badjić and N. M. Kostić, *J. Am. Chem. Soc.*, 2004, **126**, 696–697.
- J. Suh and W. S. Chei, *Curr. Opin. Chem. Biol.*, 2008, **12**, 207–213.



- 22 A. M. Embaby, L. P. W. M. Lelieveldt, F. Diness and M. Meldal, *Chem. - Eur. J.*, 2018, **24**, 17424–17428.
- 23 J. Suh, S. Yoo, M. Kim, K. Jeong, J. Ahn, M.-s. Kim, P. Chae, T. Lee, J. Lee, J. Lee, Y. Jang and E. Ko, *Angew. Chem., Int. Ed.*, 2007, **46**, 7064–7067.
- 24 J. S. Derrick, J. Lee, S. J. C. Lee, Y. Kim, E. Nam, H. Tak, J. Kang, M. Lee, S. H. Kim, K. Park, J. Cho and M. H. Lim, *J. Am. Chem. Soc.*, 2017, **139**, 2234–2244.
- 25 J. A. Brannigan, G. Dodson, H. J. Duggleby, P. C. E. Moody, J. L. Smith, D. R. Tomchick and A. G. Murzin, *Nature*, 1995, **378**, 416–419.
- 26 P. Chen and M. Hochstrasser, *Cell*, 1996, **86**, 961–972.
- 27 M. S. Wolfe, W. Xia, B. L. Ostaszewski, T. S. Diehl, W. T. Kimberly and D. J. Selkoe, *Nature*, 1999, **398**, 513–517.
- 28 J. S. Rosenblum and G. Blobel, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 11370–11375.
- 29 Y. Liao, J. Pei, H. Cheng and N. V. Grishin, *J. Mol. Biol.*, 2014, **426**, 3935–3945.
- 30 R. Mody, A. Tramontano and S. Paul, *Int. J. Pept. Protein Res.*, 1994, **44**, 441–447.
- 31 S. I. Said and V. Mutt, *Science*, 1970, **169**, 1217–1218.
- 32 I. Gozes, A. Bardea, A. Reshef, R. Zamostiano, S. Zhukovsky, S. Rubinraut, M. Fridkin and D. E. Brenneman, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 427–432.
- 33 W. Hosia, W. J. Griffiths and J. Johansson, *J. Mass Spectrom.*, 2005, **40**, 142–145.
- 34 N. Rudinskiy, C. Fuerer, D. Demurtas, S. Zamorano, C. De Piano, A. G. Herrmann, T. L. Spires-Jones, P. Oeckl, M. Otto, M. P. Frosch, M. Moniatte, B. T. Hyman and A. W. Schmid, *Alzheimer's Dementia*, 2016, **12**, 996–1013.
- 35 A. Radzicka and R. Wolfenden, *J. Am. Chem. Soc.*, 1996, **118**, 6105–6109.
- 36 D. Kahne and W. C. Still, *J. Am. Chem. Soc.*, 1988, **110**, 7529–7534.
- 37 T. Mondal and B. Mandal, *Chem. Commun.*, 2020, **56**, 2348–2351.
- 38 Y. Hatakawa, R. Nakamura, M. Konishi, T. Sakane, M. Saito and T. Akizawa, *Heliyon*, 2019, **5**, e02454.
- 39 M. Meldal and K. Breddam, *Anal. Biochem.*, 1991, **195**, 141–147.
- 40 D. B. Teplow, Preparation of Amyloid β -Protein for Structural and Functional Studies, in *Methods in Enzymology*, Academic Press, 2006, vol. 413, pp. 20–33.
- 41 H. Naiki, K. Higuchi, M. Hosokawa and T. Takeda, *Anal. Biochem.*, 1989, **177**, 244–249.
- 42 P. E. Fraser, J. T. Nguyen, W. K. Surewicz and D. A. Kirschner, *Biophys. J.*, 1991, **60**, 1190–1201.
- 43 L. O. Tjernberg, D. J. E. Callaway, A. Tjernberg, S. Hahne, C. Lilliehöök, L. Terenius, J. Thyberg and C. Nordstedt, *J. Biol. Chem.*, 1999, **274**, 12619–12625.
- 44 N. Sreerama and R. W. Woody, *Anal. Biochem.*, 2000, **287**, 252–260.
- 45 A. Micsonai, F. Wien, L. Kernya, Y.-H. Lee, Y. Goto, M. Réfrégiers and J. Kardos, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, E3095–E3103.
- 46 A. Micsonai, F. Wien, v. Bulyáki, J. Kun, v. Moussong, Y.-H. Lee, Y. Goto, M. Réfrégiers and J. Kardos, *Nucleic Acids Res.*, 2018, **46**, W315–W322.
- 47 M. Zhu, S. Han, F. Zhou, S. A. Carter and A. L. Fink, *J. Biol. Chem.*, 2004, **279**, 24452–24459.
- 48 R. Kayed, A. Pensalfini, L. Margol, Y. Sokolov, F. Sarsoza, E. Head, J. Hall and C. Glabe, *J. Biol. Chem.*, 2009, **284**, 4230–4237.
- 49 H. Choi, W. Lee, G. Lee, D. S. Yoon and S. Na, *ACS Chem. Neurosci.*, 2019, **10**, 3830–3838.
- 50 Y. Kusumoto, A. Lomakin, D. B. Teplow and G. B. Benedek, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 12277–12282.
- 51 S. A. Kauffman, *The Origins of Order: Self Organization and Selection in Evolution*, Oxford University Press, 1993.
- 52 D. H. Lee, K. Severin, Y. Yokobayashi and M. R. Ghadiri, *Nature*, 1997, **390**, 591–594.
- 53 G. Ashkenasy, R. Jagasia, M. Yadav and M. R. Ghadiri, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 10872–10877.
- 54 R. Plasson, A. Brandenburg, L. Jullien and H. Bersini, *Artif. Life*, 2011, **17**, 219–236.
- 55 W. Hordijk and M. Steel, *Biosystems*, 2017, **152**, 1–10.
- 56 J. R. Nitschke, *Nature*, 2009, **462**, 736–738.
- 57 A. I. Hanopolskyi, V. A. Smaliak, A. I. Novichkov and S. N. Semenov, *ChemSystemsChem*, 2021, **3**, e2000026.
- 58 M. Jaremko, u. Jaremko, H.-Y. Kim, M.-K. Cho, C. D. Schwieters, K. Giller, S. Becker and M. Zweckstetter, *Nat. Chem. Biol.*, 2013, **9**, 264–270.
- 59 T. Ikenoue, Y.-H. Lee, J. Kardos, M. Saiki, H. Yagi, Y. Kawata and Y. Goto, *Angew. Chem., Int. Ed.*, 2014, **53**, 7799–7804.
- 60 J. Greenwald and R. Riek, *J. Mol. Biol.*, 2012, **421**, 417–426.
- 61 Y. Liang, D. G. Lynn and K. M. Berland, *J. Am. Chem. Soc.*, 2010, **132**, 6306–6308.
- 62 R. F. Rengifo, A. Sementilli, Y. Kim, C. Liang, N. X. Li, A. K. Mehta and D. G. Lynn, *ChemSystemsChem*, 2020, **2**, e2000007.
- 63 D. Segré, D. Ben-Eli and D. Lancet, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, **97**, 4112–4117.
- 64 C. Vlad, K. Lindner, C. Karreman, S. Schildknecht, M. Leist, N. Tomczyk, J. Rontree, J. Langridge, K. Danzer, T. Ciossek, A. Petre, M. L. Gross, B. Hengerer and M. Przybylski, *Chembiochem*, 2011, **12**, 2740–2744.
- 65 J. G. Moe, E. J. Davidowitz and P. Lopez, Tau protease composition and methods of use, *US Pat.* US20140286954, May 18, 2012.
- 66 A. Bigi, R. Cascella, F. Chiti and C. Cecchi, *BioEssays*, 2022, **44**, 2200086.
- 67 S. A. Kotler, P. Walsh, J. R. Brender and A. Ramamoorthy, *Chem. Soc. Rev.*, 2014, **43**, 6692–6700.
- 68 B. Lyons, M. Friedrich, M. Raftery and R. Truscott, *Anal. Chem.*, 2016, **88**, 2675–2684.
- 69 J. Dunys, A. Valverde and F. Checler, *J. Biol. Chem.*, 2018, **293**, 15419–15428.
- 70 N. C. Wildburger, T. J. Esparza, R. D. LeDuc, R. T. Fellers, P. M. Thomas, N. J. Cairns, N. L. Kelleher, R. J. Bateman and D. L. Brody, *Sci. Rep.*, 2017, **7**, 9520.



- 71 M. Lalowski, A. Golabek, C. A. Lemere, D. J. Selkoe, H. M. Wisniewski, R. C. Beavis, B. Frangione and T. Wisniewski, *J. Biol. Chem.*, 1996, **271**, 33623–33631.
- 72 H. Jang, F. T. Arce, S. Ramachandran, R. Capone, R. Azimova, B. L. Kagan, R. Nussinov and R. Lal, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 6538–6543.
- 73 N. N. Nalivaeva, L. R. Fisk, N. D. Belyaev and A. J. Turner, *Curr. Alzheimer Res.*, 2008, **5**, 212–224.
- 74 O. Taran, C. Chen, T. O. Omosun, M.-C. Hsieh, A. Rha, J. T. Goodwin, A. K. Mehta, M. A. Grover and D. G. Lynn, *Philos. Trans. R. Soc. London, Ser. A*, 2017, **375**, 20160356.
- 75 C. P. J. Maury, *Cell. Mol. Life Sci.*, 2018, **75**, 1499–1507.
- 76 B. J. Cafferty, A. S. Y. Wong, S. N. Semenov, L. Belding, S. Gmür, W. T. S. Huck and G. M. Whitesides, *J. Am. Chem. Soc.*, 2019, **141**, 8289–8295.
- 77 L. R. Marshall, M. Jayachandran, Z. Lengyel-Zhand, C. M. Rufo, A. Kriews, M.-C. Kim and I. V. Korendovych, *ChemBioChem*, 2020, **21**, 2611–2614.
- 78 M. Frenkel-Pinter, M. Samanta, G. Ashkenasy and L. J. Leman, *Chem. Rev.*, 2020, **120**, 4707–4765.
- 79 F. Sheehan, D. Sementa, A. Jain, M. Kumar, M. Tayarani-Najjaran, D. Kroiss and R. V. Ulijn, *Chem. Rev.*, 2021, **121**, 13869–13914.
- 80 D. H. Lee, K. Severin, Y. Yokobayashi and M. R. Ghadiri, *Nature*, 1997, **390**, 591–594.

